Zabermawi, Nidal Mohammed Omar
Alyhaiby, Amani H.
El-Bestawy, Ebtesam A.
Funding for this research was provided by:
King Abdulaziz City for Science and Technology (1-18-01-0009-0218, 1-18-01-0009-0218, 1-18-01-0009-0218)
Article History
Received: 15 July 2022
Accepted: 1 November 2022
First Online: 7 November 2022
Competing interests
: Dr. Pejler and Adner report that the concept of using monensin as an anti-mast cell agent is currently under patenting. All the other authors declare that there is no conflict of interest.